Ipamorelin vs. Egrifta (Tesamorelin): When to Pick One, the Other, or Stack Both

What These Two Peptides Actually Do (and Why Women Ask About Both)

Ipamorelin and tesamorelin both raise growth hormone, but they do it through completely different mechanisms, and that difference matters when you are deciding whether to use one or both.

Ipamorelin is a synthetic growth hormone releasing peptide (GHRP). It binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, triggering a clean, short pulse of GH release with minimal spillover into cortisol or prolactin pathways. That selectivity is why practitioners prefer it over older GHRPs like GHRP-6 or GHRP-2, which reliably spike appetite and cortisol. Tesamorelin, sold as Egrifta, is a stabilized analogue of growth hormone releasing hormone (GHRH). It binds the GHRH receptor and drives a sustained increase in pulsatile GH secretion over hours. The FDA approved tesamorelin in 2010 specifically for HIV-associated lipodystrophy, where it reduced trunk visceral adipose tissue by a mean of 15.2% versus placebo at 26 weeks in the IGMOST trial.

Women are increasingly asking about both because the GH axis matters deeply for body composition, sleep, bone density, and insulin sensitivity. Those functions change across every life stage. GH secretion in women is already higher than in men during reproductive years (estrogen amplifies GH pulse amplitude), but it falls sharply in perimenopause and continues declining after menopause, dropping roughly 14% per decade after age 30. The symptoms women attribute to "metabolic slowdown" in their 40s and 50s, including central fat gain, poor sleep, and muscle loss, overlap substantially with declining GH tone. That is why the conversation about these peptides shows up in perimenopause and menopause clinics more than anywhere else.

The Mechanism Difference: GHRP vs. GHRH

Understanding the receptor-level difference tells you exactly when stacking adds value versus when it is redundant.

How Ipamorelin Works

Ipamorelin mimics ghrelin and stimulates GH release at both the hypothalamus and the pituitary. Its short half-life (about 2 hours) means each injection produces one discrete GH pulse. Because it does not meaningfully stimulate adrenocorticotropin (ACTH) or cortisol at therapeutic doses, as shown in the original Raun et al. Rat studies, it is considered the cleanest GHRP available. Animal data also shows it preserves bone density and lean mass without the appetite surge associated with GHRP-6.

How Tesamorelin Works

Tesamorelin binds the GHRH receptor and increases the amplitude of each natural GH pulse the pituitary already wants to make. It does not add an artificial pulse. Instead it makes your own pulses bigger and more sustained. Its half-life is longer than native GHRH (about 26 minutes vs. A few minutes for endogenous GHRH) because of its trans-3-hexenoic acid modification, which protects it from rapid DPP-IV degradation. The result is a more prolonged stimulation of somatotroph cells compared with ipamorelin's quick ghrelin-receptor hit.

Why the Stack Works in Theory

GHRH (tesamorelin) + GHRP (ipamorelin) act on separate receptors and show additive or synergistic GH release in animal models. Combination between GHRH and GHRP was documented in human studies as far back as 1996 by Bowers et al., showing that combined administration produces a GH response larger than either agent alone. The stack attempts to replicate this: tesamorelin primes the somatotroph, ipamorelin triggers the release. These combination data come from studies using IV or high-dose peptides in healthy men and patients with GH deficiency, not from women using subcutaneous off-label protocols. The evidence gap is real and must be stated plainly.

Who Should Use Tesamorelin Alone

Tesamorelin alone is the stronger, better-evidenced choice for visceral fat reduction in most women. Period.

The IGMOST trial enrolled 412 patients, followed them for 52 weeks, and showed durable visceral fat reduction that reversed when the drug was stopped. That is the only large, randomized, placebo-controlled dataset for either of these agents. Tesamorelin also has published IGF-1 and lipid data, known dose ranges, and a clear prescribing insert.

Women Who Fit the Tesamorelin-Alone Profile

• Perimenopausal or postmenopausal women with documented visceral adiposity and no contraindications
• Women who want evidence-backed dosing (2 mg once daily) without adding an unapproved agent
• Women using GLP-1 medications (semaglutide, tirzepatide) who also want to address the GH-IGF-1 axis separately, since GLP-1s do not raise GH
• Women with prior history of hypersensitivity to GHRPs, where avoiding ipamorelin's ghrelin pathway is prudent

Women Who May Not Respond as Well to Tesamorelin Alone

Tesamorelin works by amplifying your existing GHRH-driven GH pulses. If your pituitary somatotroph reserve is low (older postmenopausal women, women with a history of pituitary pathology, or women on high-dose glucocorticoids that suppress GH axis), the response to tesamorelin alone may be blunted. In that context, adding a GHRP like ipamorelin to also stimulate the ghrelin receptor provides a second, independent pathway to GH release.

Who Should Use Ipamorelin Alone

Ipamorelin alone suits women who want a light, daily GH pulse for sleep quality, recovery, and lean body composition without the cost and prescription burden of Egrifta.

Tesamorelin requires a prescription and, off-label, carries a cost of several hundred dollars per month. Ipamorelin is peptide-therapy territory: not FDA-approved, available through compounding pharmacies, and substantially less expensive. For women in their 30s or early 40s in the reproductive years, whose GH axis is not yet severely blunted, a modest ipamorelin protocol may be entirely adequate.

Ipamorelin-Alone Scenarios

• Women 30-45 with primary goals of improved sleep architecture and muscle recovery, not visceral fat pathology
• Women using ipamorelin alongside resistance training to support lean mass during a caloric deficit
• Women with PCOS who want to explore GH pulsatility without raising cortisol (since cortisol worsens insulin resistance in PCOS). There are no PCOS-specific ipamorelin trials, but the cortisol-sparing profile is mechanistically attractive
• Women who are actively trying to conceive and have not yet confirmed contraception plans (tesamorelin is rated Pregnancy Category X; ipamorelin has no category but must also be avoided)

The lack of human RCT data for ipamorelin is a legitimate concern. Every claim about ipamorelin's effects in women is extrapolated from animal studies, the GHRP mechanistic literature, and practitioner-reported outcomes. If you use it, you are accepting a higher evidence uncertainty than with tesamorelin.

The Stack: Ipamorelin Plus Tesamorelin Together

Combining both peptides aims to saturate two separate GH-stimulating pathways simultaneously. The theoretical benefit is a larger total GH pulse amplitude than either agent provides alone, which should produce greater IGF-1 elevation, more visceral fat lipolysis, and better lean-mass preservation.

A decision framework for the stack, based on WomanRx clinical review:

| Goal | Solo Tesamorelin | Solo Ipamorelin | Stack | |---|---|---|---| | Visceral fat, documented, postmenopause | First choice | Weak evidence alone | Consider if poor solo response | | Sleep and recovery, reproductive years | Not necessary | Reasonable | Overkill | | Lean mass during deficit, perimenopause | Useful | Useful | Reasonable if budget allows | | PCOS, insulin resistance | Limited data | Theoretical benefit | Insufficient evidence | | HIV lipodystrophy (on-label) | Approved | Not studied | Off-label; no RCT | | GH deficiency, pituitary reserve low | Partially effective | Insufficient alone | Strongest case for stack |

Practical Stack Protocol (Practitioner-Guided Only)

The most commonly reported stack in clinical peptide practice pairs tesamorelin 2 mg once daily (evening) with ipamorelin 100-300 mcg subcutaneous, 30-60 minutes before sleep. The timing targets the natural nocturnal GH surge, which peaks in the first two hours of slow-wave sleep. Women should start at the lower ipamorelin dose (100 mcg) because estrogen status amplifies GH pulse amplitude, and premenopausal women may be more sensitive to combined stimulation.

Tesamorelin's IGF-1 elevating effect is dose-consistent at 2 mg daily, so the approved dose should not be exceeded. Adding ipamorelin is off-label stacking on top of an already off-label (outside HIV) tesamorelin use. Both layers carry regulatory and evidence uncertainty outside the HIV-lipodystrophy indication.

Cycle lengths reported by practitioners range from 12 to 24 weeks on, followed by 4-8 weeks off, to prevent somatostatin upregulation (the brain's brake on GH release that activates with sustained stimulation). There are no published RCTs validating this cycling approach.

Sex-Specific Physiology: Why Dosing in Women Is Not the Same as in Men

Most peptide dosing conventions come from studies in men or in mixed-sex populations where male data dominates. Women have fundamentally different GH physiology.

Estrogen increases GH pulse amplitude and reduces IGF-1 clearance. Premenopausal women with intact estradiol already have higher baseline GH pulsatility than age-matched men. Studies using frequent blood sampling show women secrete roughly twice as much GH per 24 hours as men, though this narrows after menopause. The practical implication: a dose of ipamorelin that produces a modest GH pulse in a postmenopausal woman might overshoot in a 35-year-old with normal estradiol, producing water retention, joint aching, or paresthesias (the most common GH excess side effects).

Progesterone, by contrast, mildly blunts GH secretion in the luteal phase. Some women report that the same ipamorelin dose feels less effective in the days before menstruation. This is pharmacodynamically plausible but has not been formally studied.

After menopause, the loss of estrogen flattens GH pulsatility significantly. Women on menopausal hormone therapy (MHT) with oral estrogen may have paradoxically lower IGF-1 than women on transdermal estrogen, because oral estrogen causes a first-pass hepatic GH resistance effect. A meta-analysis by Ho et al. Confirmed that oral but not transdermal estradiol suppresses IGF-1. If you are on MHT and using tesamorelin or ipamorelin, your clinician should know your estrogen route: transdermal estradiol will allow the peptide to work more efficiently on the GH-IGF-1 axis than oral.

Pregnancy, Lactation, and Contraception

Both peptides must be stopped before attempting pregnancy. Neither is safe in pregnancy.

Tesamorelin carries an FDA Pregnancy Category X designation, meaning animal studies show fetal harm and the risk clearly outweighs any potential benefit. It is contraindicated in pregnancy, period. The prescribing information also states that women of reproductive potential should use effective contraception during treatment.

Ipamorelin has no FDA pregnancy category because it is not FDA-approved, but that absence of a rating does not imply safety. GH and IGF-1 signaling are deeply involved in placental development and fetal growth. Artificially elevating GH pulsatility during organogenesis carries theoretical teratogenic risk even if direct human data is lacking. No human pregnancy exposure data exists for ipamorelin. Avoid it in pregnancy and discontinue at least one full menstrual cycle before attempting conception to allow GH axis normalization.

Lactation safety is unknown for both peptides. Neither has been studied in breastfeeding women. IGF-1 is present in breast milk naturally, but whether exogenously elevated maternal IGF-1 meaningfully changes milk IGF-1 concentration is unstudied. The conservative standard is to avoid both during lactation.

Contraception requirement: Any woman of reproductive age using tesamorelin must use reliable contraception (hormonal methods, copper IUD, barrier plus additional method) throughout treatment. This requirement should be documented in your prescribing visit.

Postpartum women should wait until breastfeeding is fully weaned and they have medical clearance before starting either peptide.

Who This Is Right For and Who Should Not Use It

May Be Appropriate (with clinician oversight)

• Postmenopausal women with central adiposity and no active malignancy
• Perimenopausal women with documented GH-axis decline who have not responded to lifestyle alone
• Women post-bariatric surgery with ongoing visceral fat concerns
• Women with well-controlled type 2 diabetes monitored closely (both peptides can affect glucose; tesamorelin did not worsen glycemic control at 26 weeks in IGMOST but IGF-1 elevation warrants monitoring)

Should Not Use

• Women who are pregnant, breastfeeding, or trying to conceive
• Women with active or suspected malignancy. GH and IGF-1 are mitogenic; both agents are contraindicated in active cancer per tesamorelin prescribing guidance
• Women with pituitary tumors or untreated hypothyroidism (thyroid hormone is required for normal GH signaling; hypothyroidism blunts GH response and should be treated before starting any GH secretagogue)
• Women with severe fluid retention syndromes or carpal tunnel already present
• Women on high-dose glucocorticoids (suppress GH axis, reduce peptide efficacy, and compound metabolic risk)

Monitoring: What Labs to Track and When

Neither peptide is a set-and-forget therapy.

IGF-1 is the primary biomarker for GH axis activity. Your clinician should check a fasting IGF-1 before starting, again at 6-8 weeks, and every 3 months during ongoing therapy. The target is the upper quarter of the age-appropriate reference range, not supraphysiologic values. Fasting glucose and HbA1c matter because GH is counter-regulatory to insulin. Tesamorelin modestly raises fasting glucose in some patients; women with insulin resistance or pre-diabetes need quarterly glucose monitoring. A lipid panel at baseline and at 6 months is reasonable given tesamorelin's effects on triglycerides (it typically improves them in lipodystrophy but the effect in metabolically healthy women is less characterized). Thyroid function should be checked at baseline.

If IGF-1 exceeds the upper limit of normal, reduce or stop the peptide. Do not chase a higher number.

The Honest Evidence Audit

"Most studies show" is not good enough here. Let's be precise.

Tesamorelin has three published RCTs supporting visceral fat reduction in HIV-lipodystrophy, which is a metabolic phenotype that does not map perfectly onto postmenopausal central adiposity or PCOS. The extension data show that fat returns when the drug stops. No RCT exists for tesamorelin in women with primary obesity, PCOS, or menopause-related body composition change. Evidence for those uses is extrapolated from mechanism and clinician experience.

Ipamorelin has no published human RCT at any dose or indication. The foundational paper is an animal study. Everything in clinical practice is extrapolated. The stack (ipamorelin plus tesamorelin) has no published human trial at all.

As WomanRx reviewer Dr. Maya Okafor, MD, notes: "Women asking about these peptides deserve a straight answer about the evidence gap. Tesamorelin has solid RCT backing for visceral fat in a specific population. Ipamorelin as a stack partner is mechanistically rational but clinically unvalidated. I will prescribe the combination selectively, with close IGF-1 monitoring, to perimenopausal or postmenopausal patients who have not met goals on tesamorelin alone, not as a first step."

That framing should guide your conversation with your own clinician. Mechanistic plausibility is not the same as proven efficacy, and the women's-health evidence base here specifically is thin. Women were underrepresented in the original tesamorelin trials (the HIV-lipodystrophy population skewed heavily male), so even the strongest dataset for these peptides applies to women only by extrapolation.

Starting a Conversation With Your Clinician

Bring these specific questions to your prescribing clinician:

• What is my current IGF-1 and does it support adding a GH secretagogue?
• Is my thyroid function optimized before we start?
• If I am on MHT, am I using transdermal estradiol, and does that affect our target IGF-1 range?
• How will we know after 12 weeks whether this is working?
• What is the plan if my fasting glucose rises?

A 12-week trial with before-and-after DEXA-measured visceral fat area (or at minimum waist circumference and IGF-1) gives you an objective endpoint. If visceral fat has not moved meaningfully by 12-16 weeks on tesamorelin, adding ipamorelin or switching strategy is a reasonable next conversation.